AtriCure Stock News

Low-priced stocks to buy with the potential to double within the next year or so have inherent appeal for investors. Individual shares are affordable making it relatively easy to establish a stake.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o

AtriCure, Inc. (NASDAQ:ATRC ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief Executive Officer Angie W

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimat

AtriCure (ATRC) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.23 per share a year ago.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op

AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o

AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street esti

AtriCure (ATRC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.09 per share a year ago.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op

Get a deeper insight into the potential performance of AtriCure (ATRC) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o